DIAMEDICA INC.

Patent Owner

Watch Compare Add to Portfolio

Stats

Details

Patent Activity in the Last 10 Years

Technologies

Intl Class Technology Matters Rank in Class
 
  
 
A61K PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES 7248
 
  
 
C12N MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF 3164
 
  
 
A61P THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS 247

Top Patents (by citation)

Upgrade to the Professional Level to View Top Patents for this Owner. Learn More

Recent Publications

Publication # Title Filing Date Pub Date Intl Class
2017/0340,559 FORMULATIONS OF HUMAN TISSUE KALLIKREIN-1 FOR PARENTERAL DELIVERY AND RELATED METHODSMar 01, 17Nov 30, 17[A61K]

Recent Patents

Patent # Title Filing Date Issue Date Intl Class
9839678 Human tissue kallikrein 1 glycosylation isoformsMay 12, 16Dec 12, 17[A61K, C12N, A61P]
9616015 Formulations of human tissue kallikrein-1 for parenteral delivery and related methodsJun 11, 15Apr 11, 17[A61K]
9364521 Human tissue kallikrein 1 glycosylation isoformsApr 02, 15Jun 14, 16[A61K, C12N, A61P]
7622447 Use of glutathione synthesis stimulating compounds in reducing insulin resistanceJan 27, 03Nov 24, 09[A61K, C01B]
5561165 Method for treating insulin resistanceDec 01, 94Oct 01, 96[A61K]

Expired/Abandoned/Withdrawn Patents

Patent # Title Status Filing Date Issue/Pub Date Intl Class
2014/0134,152 COMPOSITIONS AND METHODS FOR TREATING DIABETESAbandonedMay 04, 12May 15, 14[A61K]
2014/0017,242 ANTI-BRADYKININ B2 RECEPTOR (BKB2R) MONOCLONAL ANTIBODYAbandonedDec 01, 11Jan 16, 14[C07K]
2013/0323,222 HUMAN TISSUE KALLIKREIN 1 GLYCOSYLATION ISOFORMSAbandonedJun 04, 13Dec 05, 13[C12N]
2013/0315,891 FORMULATIONS OF HUMAN TISSUE KALLIKREIN-1 FOR PARENTERAL DELIVERY AND RELATED METHODSAbandonedMay 24, 13Nov 28, 13[A61K]
2013/0224,230 THERAPEUTIC USES OF GLANDULAR KALLIKREINAbandonedNov 01, 12Aug 29, 13[A61K]
8501695 Tissue kallikrein for the treatment of diseases associated with amyloid proteinExpiredJul 18, 08Aug 06, 13[A61K, C12N]
2013/0089,564 Therapeutic Uses of Glandular KallikreinAbandonedAug 21, 12Apr 11, 13[A61K]
2012/0276,019 TISSUE KALLIKREIN FOR THE TREATMENT OF PARKINSON'S DISEASEAbandonedJun 12, 12Nov 01, 12[A61K, A61P, A61N]
2012/0070,425 TISSUE KALLIKREIN FOR THE TREATMENT OF PANCREATIC Beta-CELL DYSFUNCTION AND FOR Beta-CELL PROLIFERATIONAbandonedSep 23, 11Mar 22, 12[A61K, A61P]
2011/0150,781 TISSUE KALLIKREIN FOR THE TREATMENT OF PARKINSON'S DISEASEAbandonedJul 24, 09Jun 23, 11[A61K, A61P]
2010/0008,899 METHODS OF DIAGNOSIS AND TREATMENT FOR METABOLIC DISORDERSAbandonedJul 26, 07Jan 14, 10[A61K, C12Q, A61P]
2009/0324,701 COMPOSITIONS CONTAINING (S)-BETHANECHOL AND THEIR USE IN THE TREATMENT OF INSULIN RESISTANCE, TYPE 2 DIABETES, GLUCOSE INTOLERANCE AND RELATED DISORDERSAbandonedJan 19, 07Dec 31, 09[A61K, A61P]
2009/0162,342 THERAPEUTIC USES OF GLANDULAR KALLIKREINAbandonedOct 15, 08Jun 25, 09[A61K, A61P]
2007/0238,762 Use of Antagonists of Hepatic Sympathetic Nerve ActivityAbandonedSep 15, 04Oct 11, 07[A61K]
2007/0224,209 Therapeutic uses of glandular kallikreinAbandonedFeb 12, 07Sep 27, 07[A61K]
7195759 Therapeutic uses of glandular kallikreinExpiredJun 06, 02Mar 27, 07[A61K]
2007/0009,438 Method for diagnosing diabetes type 2 using standardized mixed meal and calculated index valuesAbandonedAug 05, 04Jan 11, 07[A61K, C12Q, G06F]
2005/0119,272 Use of phosphodiesterase antagonists to treat insulin resistanceAbandonedJan 12, 05Jun 02, 05[A61K]
2004/0151,785 Method for treating insulin resistance through hepatic nitric oxideAbandonedJan 21, 04Aug 05, 04[A61K]
2003/0235,609 Use of cholinesterase antagonists to treat insulin resistanceAbandonedJan 24, 03Dec 25, 03[A61K]

View all patents..

Top Inventors for This Owner

Upgrade to the Professional Level to View Top Inventors for this Owner. Learn More

We are sorry but your current selection exceeds the maximum number of comparisons () for this membership level. Upgrade to our Level for up to -1 comparisons!

We are sorry but your current selection exceeds the maximum number of portfolios (0) for this membership level. Upgrade to our Level for up to -1 portfolios!.